Your session is about to expire
← Back to Search
Phosphodiesterase Inhibitor
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
N/A
Waitlist Available
Led By Jonathan G Stine, MD
Research Sponsored by Patrick Northup, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Summary
Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.
Eligible Conditions
- Hepatorenal Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants With Treatment Success
Secondary study objectives
Incidence of Treatment Failure
Number of Participants With Combined Outcome of Treatment Success and Partial Response
Overall Survival
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TreatmentExperimental Treatment2 Interventions
Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR \<10 for 90 days in addition to standard AMO therapy
Group II: PlaceboPlacebo Group2 Interventions
This is a standard placebo pill.
Find a Location
Who is running the clinical trial?
Patrick Northup, MDLead Sponsor
Patrick G Northup, MD MHSStudy DirectorUniversity of Virginia
Jonathan G Stine, MDPrincipal InvestigatorUniversity of Virginia
3 Previous Clinical Trials
60 Total Patients Enrolled